MA44993A - Polypeptides de fusion cd40l-fc et procédés d'utilisation associés - Google Patents

Polypeptides de fusion cd40l-fc et procédés d'utilisation associés

Info

Publication number
MA44993A
MA44993A MA044993A MA44993A MA44993A MA 44993 A MA44993 A MA 44993A MA 044993 A MA044993 A MA 044993A MA 44993 A MA44993 A MA 44993A MA 44993 A MA44993 A MA 44993A
Authority
MA
Morocco
Prior art keywords
cd40l
fusion polypeptides
associated procedures
procedures
polypeptides
Prior art date
Application number
MA044993A
Other languages
English (en)
Inventor
Manuel Baca
Stacey Drabic
Peter Emtage
Ronald Herbst
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MA44993A publication Critical patent/MA44993A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Epidemiology (AREA)
MA044993A 2016-05-13 2017-05-12 Polypeptides de fusion cd40l-fc et procédés d'utilisation associés MA44993A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662336129P 2016-05-13 2016-05-13

Publications (1)

Publication Number Publication Date
MA44993A true MA44993A (fr) 2019-03-20

Family

ID=60267851

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044993A MA44993A (fr) 2016-05-13 2017-05-12 Polypeptides de fusion cd40l-fc et procédés d'utilisation associés

Country Status (18)

Country Link
US (1) US10975155B2 (fr)
EP (1) EP3455263A4 (fr)
JP (1) JP2019523636A (fr)
KR (1) KR20190004319A (fr)
CN (1) CN109153729A (fr)
AR (1) AR108468A1 (fr)
AU (1) AU2017264944A1 (fr)
BR (1) BR112018072953A2 (fr)
CA (1) CA3022636A1 (fr)
CL (1) CL2018003141A1 (fr)
CO (1) CO2018013104A2 (fr)
IL (1) IL262727A (fr)
MA (1) MA44993A (fr)
MX (1) MX2018013762A (fr)
RU (1) RU2018138703A (fr)
SG (1) SG11201809374VA (fr)
TW (1) TW201741337A (fr)
WO (1) WO2017197231A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3103875A1 (fr) * 2008-07-21 2016-12-14 Apogenix AG Molécules à chaîne unique tnfsf
CN105873606B (zh) 2013-09-11 2020-12-29 米迪缪尼有限公司 用于治疗肿瘤的抗b7-h1抗体
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US11298420B2 (en) * 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
RU2769513C2 (ru) 2017-01-05 2022-04-01 Кахр Медикал Лтд. Слитый белок pd1-4-1bbl и способы его применения
WO2018127918A1 (fr) 2017-01-05 2018-07-12 Kahr Medical Ltd. Protéine de fusion sirp alpha-cd70 et ses procédés d'utilisation
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
PL3565828T3 (pl) 2017-01-05 2022-04-04 Kahr Medical Ltd. Białko fuzyjne SIRP1 ALFA-41BBL i sposoby jego zastosowania
KR102945860B1 (ko) 2018-07-11 2026-03-31 카 메디컬 리미티드 SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법
CA3104778A1 (fr) 2018-07-11 2020-01-16 Kahr Medical Ltd. Variant de la proteine de fusion pd1-4-1bbl et procedes d'utilisation associes
WO2020163534A1 (fr) * 2019-02-06 2020-08-13 The Regents Of The University Of California Polypeptides cd40l négatifs dominants
KR20210006301A (ko) * 2019-07-08 2021-01-18 주식회사 프로젠 신규 융합단백질 및 그의 용도
JP2022547061A (ja) * 2019-09-05 2022-11-10 アストラゼネカ・アクチエボラーグ 進展型小細胞肺癌（ｅｓ－ｓｃｌｃ）の治療のための組成物及び方法
JP7807076B2 (ja) * 2019-12-13 2026-01-27 キュージーン インコーポレイテッド 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用
US20230123454A1 (en) * 2020-01-23 2023-04-20 Genexine, Inc. Fusion protein comprising pd-l1 protein and use thereof
KR20230042691A (ko) * 2020-06-04 2023-03-29 카리스마 테라퓨틱스 인코포레이티드 키메라 항원 수용체에 대한 신규한 작제물
JP2024512424A (ja) * 2021-03-12 2024-03-19 ヤンセン バイオテツク，インコーポレーテツド 生物工学による免疫調節性融合タンパク質組成物
WO2023088876A1 (fr) * 2021-11-16 2023-05-25 Apogenix Ag Modulateurs immunitaires multi-spécifiques
JP2026513789A (ja) 2023-04-05 2026-05-01 エフ． ホフマン－ラ ロシュ アーゲー 抗体発現細胞のインビトロ培養方法
CN119613573B (zh) * 2025-02-14 2025-05-30 浙江大学 一种CD40L-Fc融合蛋白、基因片段、重组质粒、重组细胞以及制备方法和用途
CN120590545A (zh) * 2025-06-09 2025-09-05 上海市胸科医院 包括cd40l和il7的融合蛋白及其在制备治疗肿瘤药物中的应用
CN120943974A (zh) * 2025-07-31 2025-11-14 上海市胸科医院 Cd40l-il-21融合蛋白及其制备与在制备治疗肿瘤药物中的用途
CN120888000B (zh) * 2025-07-31 2026-05-08 上海市胸科医院 Cd40l-il-2融合蛋白及其制备与在制备治疗肿瘤药物中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9709447A (es) * 1995-06-07 1998-02-28 Immunex Corp Nueva muteina cd4ol.
EP0956030A4 (fr) * 1996-07-08 2001-11-28 Univ Columbia Applications therapeutiques de la technologie t-bam (cd40l) pour le traitement des maladies concernant les cellules des muscles lisses
US6774225B2 (en) 1999-04-15 2004-08-10 Hong Kong University Of Science & Technology Antigenized antibody vaccine for foot-and-mouth disease
AU2001283496A1 (en) * 2000-07-25 2002-02-05 Immunomedics, Inc. Multivalent target binding protein
PL208287B1 (pl) * 2001-12-21 2011-04-29 Immunex Corp Polipeptyd fuzyjny, sposób jego wytwarzania oraz kodujący go kwas nukleinowy, komórka gospodarza, rekombinowany wektor oraz sposób jego konstruowania
MX2007014564A (es) * 2005-05-20 2008-02-07 Ablynx Nv Anticuerpos de vhh de dominio unico contra el factor de von willebrand.
EP3103875A1 (fr) 2008-07-21 2016-12-14 Apogenix AG Molécules à chaîne unique tnfsf
MA41460A (fr) * 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
BR112017023646A2 (pt) * 2015-05-04 2018-07-17 Apogenix Ag proteínas agonistas de receptor de cd40 de cadeia simples

Also Published As

Publication number Publication date
WO2017197231A1 (fr) 2017-11-16
CN109153729A (zh) 2019-01-04
IL262727A (en) 2018-12-31
EP3455263A4 (fr) 2020-01-01
KR20190004319A (ko) 2019-01-11
US10975155B2 (en) 2021-04-13
MX2018013762A (es) 2019-03-28
JP2019523636A (ja) 2019-08-29
CO2018013104A2 (es) 2018-12-14
AR108468A1 (es) 2018-08-22
SG11201809374VA (en) 2018-11-29
CL2018003141A1 (es) 2018-12-28
TW201741337A (zh) 2017-12-01
AU2017264944A1 (en) 2018-12-20
RU2018138703A (ru) 2020-06-15
EP3455263A1 (fr) 2019-03-20
BR112018072953A2 (pt) 2019-02-19
US20170327588A1 (en) 2017-11-16
CA3022636A1 (fr) 2017-11-16

Similar Documents

Publication Publication Date Title
EP3455263A4 (fr) Polypeptides de fusion cd40l-fc et procédés d'utilisation associés
EP3655006A4 (fr) Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation
MA44507A (fr) Récepteurs chimères de flt3 et leurs procédés d'utilisation
EP3504245A4 (fr) Polypeptides chimériques clivables de manière protéolytique et leurs procédés d'utilisation
IL263478A (en) Aerosol-generating system comprising a gel containing cartridge and a device for heating the cartridge
MA40721A (fr) Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
EP3341009A4 (fr) Ensemble de polypeptides chimériques et procédés de préparation et d'utilisation de ceux-ci
IL264590B2 (en) Polypeptides containing an FC region and uses thereof
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
EP3430058A4 (fr) Protéines de fusion à fab multispécifiques et leur utilisation
EP3390624A4 (fr) Polypeptides de modification ciblée modifiés et leurs procédés d'utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
EP3544775A4 (fr) Accouplement et pivot de rasoir
EP3349674A4 (fr) Systèmes et procédés d'espacement d'articulation
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
EP3352760A4 (fr) Polypeptides de liaison à cd3
EP3680331A4 (fr) Protéine cas9 modifiée et utilisation de celle-ci
EP3394065A4 (fr) Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés
MA41296A (fr) Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
EP3303435A4 (fr) Hydrofluoroléfines et procédés d'utilisation associés
EP3538560A4 (fr) Polypeptides de fusion gdnf et leurs procédés d'utilisation
EP3349851A4 (fr) Polypeptides photosensibles et leurs procédés d'utilisation
EP3394098A4 (fr) Anticorps anti-myostatine et procédés d'utilisation
EP3212290A4 (fr) Polypeptides de fusion de serpine et leurs procédés d'utilisation
EP3339320A4 (fr) Récepteur d'anticorps chimérique auquel est lié un anticorps anti-cotinine et utilisation de celui-ci